7 slides from CorMedix's merger presentation, Nov 9, 2026
Slide 1: Acquisition of Heron Therapeutics Commercial and Pipeline Assets
Acquisition of Heron Therapeutics Commercial and Pipeline Assets November 9, 2026 1
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “c
Slide 3: Transaction Overview and Timeline
Transaction Overview and Timeline ➢ CorMedix Therapeutics (“CorMedix”) (NASDAQ: CRMD) has announced a definitive agreement to acquire substantially all assets Transaction of Heron Therapeutics (“Heron”) (NASDAQ: HRTX), including four commercial products (ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL®) w
Slide 4: Combined CorMedix and Heron Assets
Combined CorMedix and Heron Assets Established commercial portfolio with Immediately accretive with potential products to the acute care and upside from pipeline and label expansion hematology/oncology supportive care opportunities ecosystems 11. Extends CorMedix’s portfolio into perioperative pain
Slide 5: Highlights of Heron Commercial and Pipeline Assets
Highlights of Heron Commercial and Pipeline Assets Established integrated acute care and hematology/oncology supportive care portfolio of four FDA-approved commercial brands, 1 supported by a dedicated hospital and ambulatory surgery center (ASC) sales force with a broad footprint Diversified Q3 202
Slide 6: Summary of Heron's Commercial Portfolio
Summary of Heron’s Commercial Portfolio Hematology/Oncology Care Products Acute Care Products Product Description IV NK1 receptor antagonist Extended-release 5-HT3 Ready-to-use IV NK1 receptor Dual-acting, extended-release formulated without polysorbate receptor antagonist designed antagonist offeri
Slide 7: Combined Product Portfolio
Combined Product Portfolio Creates a diversified portfolio with 12 commercial products and multiple near-term pipeline opportunities Ph III / Product Indication Pre-Clinical Ph I Ph II Commercial Registrational Hemodialysis Commercial Total Parenteral Nutrition (TPN) Ph III Hemodialysis (Pediatric l